CellRight Technologies, subsidiary of Tissue Regenix (TRX), signed a long-term, multi-year agreement with Arthrex for distribution of CellRight’s orthobiologic products that have application in spine, trauma, foot/ankle, sports medicine and general ortho procedures.
TRX acquired CellRight Technologies in 3Q17. Combined, the companies offer products for bone and soft tissue regeneration based on CellRight’s human-derived bone grafts and TRX’s dCELL® decellularization platform.
CellRight Technologies, subsidiary of Tissue Regenix (TRX), signed a long-term, multi-year agreement with Arthrex for distribution of CellRight's orthobiologic products that have application in spine, trauma, foot/ankle, sports medicine and general ortho procedures.
TRX acquired CellRight Technologies in 3Q17. Combined, the companies...
CellRight Technologies, subsidiary of Tissue Regenix (TRX), signed a long-term, multi-year agreement with Arthrex for distribution of CellRight’s orthobiologic products that have application in spine, trauma, foot/ankle, sports medicine and general ortho procedures.
TRX acquired CellRight Technologies in 3Q17. Combined, the companies offer products for bone and soft tissue regeneration based on CellRight’s human-derived bone grafts and TRX’s dCELL® decellularization platform.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
